Media coverage about Interpace Diagnostics Gr (NASDAQ:IDXG) has been trending somewhat positive on Friday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Interpace Diagnostics Gr earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the business services provider an impact score of 46.1526048912337 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
IDXG has been the subject of several recent research reports. Maxim Group set a $3.00 target price on shares of Interpace Diagnostics Gr and gave the company a “buy” rating in a report on Wednesday, March 28th. HC Wainwright set a $3.00 price target on shares of Interpace Diagnostics Gr and gave the stock a “buy” rating in a report on Friday, March 16th. Laidlaw initiated coverage on shares of Interpace Diagnostics Gr in a report on Thursday, February 22nd. They set a “buy” rating and a $4.50 price target for the company. Finally, Zacks Investment Research upgraded shares of Interpace Diagnostics Gr from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday, May 9th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Interpace Diagnostics Gr has an average rating of “Buy” and an average price target of $2.88.
Get Interpace Diagnostics Gr alerts:
Shares of Interpace Diagnostics Gr traded down $0.04, reaching $0.85, during midday trading on Friday, according to MarketBeat.com. 527,030 shares of the stock were exchanged, compared to its average volume of 438,725. The company has a market cap of $24.64 million, a PE ratio of -1.04 and a beta of 1.77. Interpace Diagnostics Gr has a 52-week low of $0.72 and a 52-week high of $1.94.
Interpace Diagnostics Gr (NASDAQ:IDXG) last issued its quarterly earnings results on Tuesday, May 15th. The business services provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The firm had revenue of $4.81 million for the quarter, compared to analysts’ expectations of $4.30 million. Interpace Diagnostics Gr had a negative return on equity of 46.58% and a negative net margin of 103.40%. analysts expect that Interpace Diagnostics Gr will post -0.31 EPS for the current fiscal year.
About Interpace Diagnostics Gr
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.